Comparison Between Cannabidiol and Sertraline for the Modulation of Post-traumatic Stress Disorder-like Behaviors and Fear Memory in Mice

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2022 Apr 9

PMID 35396940

Authors

Xiao Han

Xiankui Song

Dake Song

Guanbo Xie

Hongyan Guo

Ning Wu

Jin Li

Affiliations

Soon will be listed here.

Abstract

Rationale And Objectives: Post-traumatic stress disorder (PTSD) is characterized by poor adaptation to a traumatic experience and disturbances in fear memory regulation, and currently lacks effective medication. Cannabidiol is a main constituent of Cannabis sativa; it has no psychotomimetic effects and has been implicated in modulating fear learning in mammals. Using a mouse PTSD model, we investigated the effects of CBD on PTSD-like behaviors and the modulation of trauma-related fear memory, a crucial process leading to core symptoms of PTSD.

Methods: We applied the modified pre-shock model to evaluated PTSD-like behaviors from days 3 to 26. The measures included the freezing time to the conditioned context, open field test, elevated plus maze test, and social interaction test. CBD and sertraline were administered at different stages of fear memory.

Results: CBD (10 mg/kg, i.p.) administration alleviated main PTSD-like symptoms in the mouse pre-shock model by attenuating trauma-related fear memory and anxiety-like behavior, and increasing social interaction behavior. The effects of CBD were apparent irrespective of whether it was administered before, during, or after re-exposure to the aversive context. However, sertraline (15 mg/kg, p.o.) was only effective when administered before the behavioral test. CBD also reduced the consolidation, retrieval, and reconsolidation of trauma-related fear memory, whereas sertraline only reduced fear-memory retrieval.

Conclusion: CBD produced anti-PTSD-like actions in mice and disrupted trauma-related fear memory by interfering with multiple aspects of fear memory processing. These findings indicate that CBD may be a promising candidate for treating PTSD.

Citing Articles

Fluoxetine Rescues Excessive Myelin Formation and Psychological Behaviors in a Murine PTSD Model.

Yin C, Luo K, Zhu X, Zheng R, Wang Y, Yu G Neurosci Bull. 2024; 40(8):1037-1052.

PMID: 39014176 PMC: 11306862. DOI: 10.1007/s12264-024-01249-4.

Dual-step pharmacological intervention for traumatic-like memories: implications from D-cycloserine and cannabidiol or clonidine in male and female rats.

Soares L, Nascimento L, Guimaraes F, Gazarini L, Bertoglio L Psychopharmacology (Berl). 2024; 241(9):1827-1840.

PMID: 38691149 DOI: 10.1007/s00213-024-06596-8.

Single-Nucleus Transcriptome Profiling from the Hippocampus of a PTSD Mouse Model and CBD-Treated Cohorts.

Xie G, Qin Y, Wu N, Han X, Li J Genes (Basel). 2024; 15(4).

PMID: 38674453 PMC: 11050643. DOI: 10.3390/genes15040519.

A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders.

Omotayo O, Lemmer Y, Mason S J Cannabis Res. 2024; 6(1):14.

PMID: 38494488 PMC: 10946130. DOI: 10.1186/s42238-024-00222-2.

The therapeutic potential of purified cannabidiol.

OSullivan S, Skov Jensen S, Nykjaer Nikolajsen G, Ziegler Bruun H, Bhuller R, Hoeng J J Cannabis Res. 2023; 5(1):21.

PMID: 37312194 PMC: 10262148. DOI: 10.1186/s42238-023-00186-9.

References

Ali R, Al Kury L, Yang K, Qureshi A, Rajesh M, Galadari S . Effects of cannabidiol on contractions and calcium signaling in rat ventricular myocytes. Cell Calcium. 2015; 57(4):290-9. DOI: 10.1016/j.ceca.2015.02.001. View

Baldwin D, Anderson I, Nutt D, Allgulander C, Bandelow B, den Boer J . Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014; 28(5):403-39. DOI: 10.1177/0269881114525674. View

Bentefour Y, Rakibi Y, Bennis M, Ba-Mhamed S, Garcia R . Paroxetine treatment, following behavioral suppression of PTSD-like symptoms in mice, prevents relapse by activating the infralimbic cortex. Eur Neuropsychopharmacol. 2015; 26(2):195-207. DOI: 10.1016/j.euroneuro.2015.12.021. View

Betthauser K, Pilz J, Vollmer L . Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health Syst Pharm. 2015; 72(15):1279-84. DOI: 10.2146/ajhp140523. View

Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde D, Brandi I . Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001; 134(4):845-52. PMC: 1573017. DOI: 10.1038/sj.bjp.0704327. View

Bonn-Miller M, Vujanovic A, Feldner M, Bernstein A, Zvolensky M . Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007; 20(4):577-86. DOI: 10.1002/jts.20243. View

Breslau N, Kessler R, Chilcoat H, Schultz L, Davis G, Andreski P . Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Arch Gen Psychiatry. 1998; 55(7):626-32. DOI: 10.1001/archpsyc.55.7.626. View

Briscione M, Michopoulos V, Jovanovic T, Norrholm S . Neuroendocrine Underpinnings of Increased Risk for Posttraumatic Stress Disorder in Women. Vitam Horm. 2017; 103:53-83. DOI: 10.1016/bs.vh.2016.08.003. View

Campos A, Ferreira F, Guimaraes F . Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res. 2012; 46(11):1501-10. DOI: 10.1016/j.jpsychires.2012.08.012. View

10.

Carrier E, Auchampach J, Hillard C . Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A. 2006; 103(20):7895-900. PMC: 1472541. DOI: 10.1073/pnas.0511232103. View

11.

Das R, Kamboj S, Ramadas M, Yogan K, Gupta V, Redman E . Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl). 2013; 226(4):781-92. DOI: 10.1007/s00213-012-2955-y. View

12.

Davidson J, Rothbaum B, van der Kolk B, Sikes C, Farfel G . Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001; 58(5):485-92. DOI: 10.1001/archpsyc.58.5.485. View

13.

Do-Monte F, Manzano-Nieves G, Quinones-Laracuente K, Ramos-Medina L, Quirk G . Revisiting the role of infralimbic cortex in fear extinction with optogenetics. J Neurosci. 2015; 35(8):3607-15. PMC: 4339362. DOI: 10.1523/JNEUROSCI.3137-14.2015. View

14.

Elbatsh M, Assareh N, Marsden C, Kendall D . Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl). 2011; 221(2):239-47. DOI: 10.1007/s00213-011-2566-z. View

15.

El-Talatini M, Taylor A, Konje J . The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril. 2009; 93(6):1989-96. DOI: 10.1016/j.fertnstert.2008.12.033. View

16.

Evans A, Formukong E, Evans F . Activation of phospholipase A2 by cannabinoids. Lack of correlation with CNS effects. FEBS Lett. 1987; 211(2):119-22. DOI: 10.1016/0014-5793(87)81420-5. View

17.

Fanselow M . Conditioned and unconditional components of post-shock freezing. Pavlov J Biol Sci. 1980; 15(4):177-82. DOI: 10.1007/BF03001163. View

18.

Fesler F . Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991; 52(9):361-4. View

19.

Fineberg N, Haddad P, Carpenter L, Gannon B, Sharpe R, Young A . The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol. 2013; 27(9):761-70. PMC: 3778981. DOI: 10.1177/0269881113495118. View

20.

Ford N . The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J Trauma Stress. 1996; 9(4):857-63. DOI: 10.1007/BF02104107. View